Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 22653976

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2012 Jul 12
First author
Messinger YH

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Messinger YH
      type
      Author
    2. name
      Gaynon PS
      type
      Author
    3. name
      Sposto R
      type
      Author
    4. name
      van der Giessen J
      type
      Author
    5. name
      Eckroth E
      type
      Author
    6. name
      Malvar J
      type
      Author
    7. name
      Bostrom BC
      type
      Author
    8. name
      Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium
      type
      CollectiveName
    Complete bibliographic record and source provenance
    authors
    1. name
      Messinger YH
      type
      Author
    2. name
      Gaynon PS
      type
      Author
    3. name
      Sposto R
      type
      Author
    4. name
      van der Giessen J
      type
      Author
    5. name
      Eckroth E
      type
      Author
    6. name
      Malvar J
      type
      Author
    7. name
      Bostrom BC
      type
      Author
    8. name
      Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium
      type
      CollectiveName
    bibliography ids
    1. nci-bib-47972b6b9a1339c559a99ff5
    book metadata
    content sha256
    e079c0cf757c59de991349b1bf52f0c80101460c99f97dbd79f1586c5f432c04
    document type
    citation
    dois
    1. 10.1182/blood-2012-04-418640
    electronic publication date
    display
    2012 May 31
    precision
    day
    year
    2012
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:22653976
    immutable id
    pubmed:22653976@e079c0cf757c59de991349b1bf52f0c80101460c99f97dbd79f1586c5f432c04
    journal
    abbreviation
    Blood
    issn electronic
    1528-0020
    issn print
    0006-4971
    issue
    2
    name
    Blood
    nlm unique id
    7603509
    pages
    285-90
    volume
    120
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      22653976
      provenance
      batch id
      c95be1d0b8cf19942816
      provider
      NCBI PubMed ESummary
      record sha256
      a1ed7c5276e623e139a7a62e904f9268825b172b03a7efd3c81bd97cd4677666
      response sha256
      a96bb680a8f3690267e009557d1b07aab71455ba44aeba18695d98a3eeb5fcf2
      retrieved at
      2026-09-09T23:46:47.691937+00:00
      publication date
      display
      2012 Jul 12
      precision
      day
      year
      2012
      publication types
      1. Clinical Trial, Phase II
      2. Journal Article
      3. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/22653976/
      title
      Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.

      Preserved source evidence · Not medical advice